Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 31.81 % |
3 Month Return | + 13.82 % |
1 Year Return | + 32.85 % |
Market Stats | |
Previous Close | ₹813.55 |
Open | ₹819.65 |
Volume | 1.16L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹1,729.47Cr |
P/E Ratio | 16.86 |
PEG Ratio | 2.14 |
Market Cap | ₹1,729.47 Cr |
P/B Ratio | 1.98 |
EPS | 46.58 |
Dividend Yield | 0.31 |
Sector | Pharmaceuticals |
ROE | 17.04 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
NA | ₹1,729.47 Cr | 68.5% | 0.50 | ₹93 Cr | ₹580 Cr | |
NA | ₹435.76 Cr | 272.24% | 0.54 | ₹28 Cr | ₹601 Cr | |
NA | ₹15.41 Cr | 278.33% | 0.50 | NA | NA | |
BUY | ₹23,100.09 Cr | 3.59% | 0.52 | NA | NA | |
NA | ₹706.49 Cr | -0.07% | 0.57 | ₹9 Cr | ₹179 Cr |
Organisation | Lincoln Pharmaceuticals Ltd |
Headquarters | Ahmedabad |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Lincoln Pharmaceuticals Ltd
Lincoln Pharma Reports Mixed Financial Results - 25 Nov, 2024
Lincoln Pharmaceuticals Reports Q2 FY25 Results - 14 Nov, 2024
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 3 quarters, 18.6 Cr → 26.33 Cr (in ₹), with an average increase of 15.8% per quarter
Price Rise
In the last 1 month, LINCOLN stock has moved up by 38.5%
Revenue Rich
Revenue is up for the last 3 quarters, 149.51 Cr → 171.19 Cr (in ₹), with an average increase of 6.5% per quarter
FII Holding Up
Foreign Institutions have increased holdings from 3.95% to 5.19% in Sep 2024 quarter
Best in 3 Years
In the last 3 years, LINCOLN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 57.1% return, outperforming this stock by 20.9%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 49.78% of holdings in Sep 2024 quarter
Retail Holding Down
Retail Investor have decreased holdings from 46.24% to 45.03% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 49.78% | 0.00 | |
Foreign Institutions | 5.19% | 31.48 | |
Mutual Funds | 0% | 85.71 | |
Retail Investors | 45.03% | ||
Others | 0% |
Lincoln Pharmaceuticals Ltd in the last 5 years
Lowest (3.58x)
March 23, 2020
Today (16.86x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (19.77x)
December 9, 2024
Lincoln Pharmaceuticals Ltd’s net profit fell -4.77% since last year same period to ₹26.33Cr in the Q2 2024-2025. On a quarterly growth basis, Lincoln Pharmaceuticals Ltd has generated 11.24% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2024, Lincoln Pharmaceuticals Ltd has declared dividend of ₹1.80 - translating a dividend yield of 0.41%.
Read More about DividendsBearish
Neutral
Bullish
Lincoln Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
Lincoln Pharmaceuticals Ltd (LINCOLN) share price today is ₹812.1
Lincoln Pharmaceuticals Ltd is listed on NSE
Lincoln Pharmaceuticals Ltd is listed on BSE
PE Ratio of Lincoln Pharmaceuticals Ltd is 16.86
PE ratio = Lincoln Pharmaceuticals Ltd Market price per share / Lincoln Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Lincoln Pharmaceuticals Ltd(LINCOLN) is 1.16L.
Today’s market capitalisation of Lincoln Pharmaceuticals Ltd(LINCOLN) is ₹1729.47Cr.
Lincoln Pharmaceuticals Ltd(LINCOLN | Price |
---|---|
52 Week High | ₹979.5 |
52 Week Low | ₹534.8 |
Lincoln Pharmaceuticals Ltd(LINCOLN) share price is ₹812.1. It is down -17.09% from its 52 Week High price of ₹979.5
Lincoln Pharmaceuticals Ltd(LINCOLN) share price is ₹812.1. It is up 51.85% from its 52 Week Low price of ₹534.8
Lincoln Pharmaceuticals Ltd(LINCOLN | Returns |
---|---|
1 Day Returns | -1.45% |
1 Month Returns | 31.81% |
3 Month Returns | 13.82% |
1 Year Returns | 32.85% |